வணிகரீதியானது விநியோகி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வணிகரீதியானது விநியோகி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வணிகரீதியானது விநியோகி Today - Breaking & Trending Today

SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer


SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
- Seasoned team to drive forward pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT)
- Follows recent appointments of Professor Ton Logtenberg as non-executive Chairman and Ray Barlow as Chief Executive Officer
News provided by
Share this article
DUBLIN, Aug. 3, 2021 /PRNewswire/
   SynOx Therapeutics Limited ( SynOx or the Company ), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), today announces the appointments of Axel Mescheder, MD as Chief Medical Officer and Broes Naeye, PhD as Chief Technology Officer, as it accelerates activities to support a registrational trial of emactuzumab in the USA and EU. ....

United States , Broes Naeye , Gray Barlow , Axel Mescheder , Synox Therapeutics Limited , Synox Senior Management Team , Synox Therapeutics , Tenosynovial Giant Cell Tumours , Chief Medical Officer , Chief Technology Officer , Chief Medical , Hoffmann La Roche , Global Product Supply Lead , Commercial Supply , Chief Executive Officer , Synox Senior Management , Celleron Therapeutics , Giant Cell Tumours , ஒன்றுபட்டது மாநிலங்களில் , ராய் பார்லோ , தலைமை மருத்துவ அதிகாரி , தலைமை தொழில்நுட்பம் அதிகாரி , தலைமை மருத்துவ , ஹாஃப்மேன் லா ரோச் , வணிகரீதியானது விநியோகி , தலைமை நிர்வாகி அதிகாரி ,

Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis


Egis Pharmaceuticals PLC Announces Registration of the First Blood-based CE IVD Precision Medicine Tool for Therapy Selection in Rheumatoid Arthritis
Share Article
Egis Pharmaceuticals PLC (Egis) received the CE In Vitro Diagnostic (IVD) Medical Device Certificate of its PREDYSTIC® Infliximab RA Kit on December 21st, 2020.
BUDAPEST, Hungary (PRWEB)
March 16, 2021
The PREDYSTIC® Infliximab RA Kit is a first-in-class, CE IVD labelled, molecular biomarker diagnostic system, suitable for predicting infliximab responsiveness in rheumatoid arthritis patients, before the first biological treatment initiation. This novel tool supports the decision making of stakeholders including rheumatologists, patients, payors, and drug developers.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder affecting around 1% of the worldwide population. Clinical therapeutic options are still limit ....

Brian Lockhart , Michelle Collins , Zsolt Holl , Aegis Pharmaceuticals , Servier Group , Business Development , Vitro Diagnostic Medical Device Regulation , Applied Biosystems , Gene Expression Taqman , Array Card , Thermo Fisher Scientific , Biological Business Development , Companion Diagnostics , Commercial Supply , Thermo Fisher , Active Pharmaceutical Ingredients , Finished Drug Products , Eastern Europe , Press Release , பிரையன் லாக்ஹார்ட் , மைக்கேல் கோலின்ஸ் , வணிக வளர்ச்சி , விட்ரோ கண்டறியும் மருத்துவ சாதனம் ஒழுங்குமுறை , பயன்படுத்தப்பட்டது உயிர் அமைப்புகள் , வரிசை அட்டை , தெர்மோ மீனவர் அறிவியல் ,

Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza


Published: Mar 12, 2021
Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE)
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19, at its facility near Houston, Texas.
“Manufacturing capacity for COVID-19 vaccines has been severely constrained, and this limitation has presented considerable challenges for vaccine developers,” said Dr. Vyjayanthi Krishnan, Ph.D., Vice President of Product Development for Altimmune. “By expanding our Lonza collaboration and commissi ....

United States , Martina Ribar Hestericov , Dirk Oehlers , Alberto Santagostino , Vipink Garg , Vyjayanthi Krishnan , Stacey Jurchison , Head Of External Communications , Lonza Group Ltd , Altimmune Inc , Swiss Exchange , University Of Alabama At Birmingham , Exchange Commission , Singapore Exchange Securities Trading Limited , Product Development For Altimmune , Dedicated Suite , Commercial Supply , Vice President , Product Development , Rgene Technologies , Chief Executive Officer , Swiss Alps , Looking Statement , Private Securities Litigation Reform Act , Media Contacts , Group Ltd ,